Key result
Long non-coding RNAs are differentially expressed in coronary artery disease and regulate endothelial cell injury, angiogenesis, and plaque formation, serving as potential diagnostic and prognostic biomarkers.
Why the study?
Differential expression of lncRNAs in CAD patients enables them to potentially serve as biomarkers for disease progression, diagnosis, and prognosis.
What is the role of long non-coding RNAs in the pathogenesis and progression of coronary artery disease?
What is the role of long non-coding RNAs in the pathogenesis and progression of coronary artery disease?
LncRNAs are implicated in the pathological mechanisms of CAD and have potential utility as diagnostic and prognostic biomarkers.
Supports lncRNA biomarker research in CAD; leaves open prospective validation before any clinical use.
Coronary artery disease (CAD), caused by coronary artery occlusion, is a common cardiovascular disease worldwide. Long non-coding RNAs (lncRNAs) are implicated in the regulation of endothelial cell injury, angiogenesis, plaque formation, and other pathological mechanisms in CAD by acting on different cell types. Some lncRNAs are significantly upregulated in CAD patients; however, other lncRNAs are significantly downregulated. Differential expression of lncRNAs in CAD patients enables them to be exploited as potential biomarkers to evaluate disease progression and diagnosis/prognosis in CAD patients. In this study, we reviewed the role of lncRNAs in the development of different clinical subtypes of CAD.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2023) conducted a review in Coronary Artery Disease. Long non-coding RNAs (lncRNAs) was evaluated. Long non-coding RNAs are differentially expressed in coronary artery disease and regulate endothelial cell injury, angiogenesis, and plaque formation, serving as potential diagnostic and prognostic biomarkers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: